Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease

Neurobiology of Disease

Volumn 96, Issue , 2016, Pages 171-185

  Melnikova, Tatiana ^a   Park, DaMin ^a   Becker, Lauren ^a   Lee, Deidre ^a   Cho, Eugenia ^a   Sayyida, Nuzhat ^a   Tian, Jing ^b   Bandeen Roche, Karen ^b   Borchelt, David R ^c   Savonenko, Alena V ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

APP expression; A oligomers; contextual fear; dorsal dentate gyrus; gender differences; habituation associated hyperactivity; novelty induced activation; sex dimorphism; tTa effects

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IIALPHA; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; PRESENILIN 1; TETRACYCLINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; BRAIN TISSUE; COGNITIVE DEFECT; CONTROLLED STUDY; DENTATE GYRUS; DORSAL HIPPOCAMPUS; FEAR CONDITIONING TEST; FEMALE; HIPPOCAMPAL CA1 REGION; IMMUNOBLOTTING; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PATHOGENESIS; PREPULSE INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SEX DIFFERENCE; STARTLE REFLEX; TRANSGENIC MOUSE; WESTERN BLOTTING; ANIMAL; ATROPHY; BIOLOGICAL MODEL; CONDITIONING; DISEASE MODEL; FEAR; GENETICS; HUMAN; LOCOMOTION; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RECOGNITION; SEX FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ATROPHY; CONDITIONING (PSYCHOLOGY); DENTATE GYRUS; DISEASE MODELS, ANIMAL; FEAR; FEMALE; HUMANS; LOCOMOTION; MALE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTATION; PRESENILIN-1; RECOGNITION (PSYCHOLOGY); SEX FACTORS; TETRACYCLINE;

EID: 84987971102     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.08.009     Document Type: Article

References (82)

1. Amaral, D.G., Witter, M.P., The three-dimensional organization of the hippocampal formation: a review of anatomical data. Neuroscience 31 (1989), 571–591.
2. Amaral, D.G., et al. The dentate gyrus: fundamental neuroanatomical organization (dentate gyrus for dummies). Prog. Brain Res. 163 (2007), 3–22.
3. Ashe, K.H., Zahs, K.R., Probing the biology of Alzheimer's disease in mice. Neuron 66 (2010), 631–645.
4. Barnes, L.L., et al. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch. Gen. Psychiatry 62 (2005), 685–691.
5. Berger-Sweeney, J., et al. Sex differences in learning and memory in mice: effects of sequence of testing and cholinergic blockade. Behav. Neurosci. 109 (1995), 859–873.
6. Borchelt, D.R., et al. A vector for expressing foreign genes in the brains and hearts of transgenic mice. Genet. Anal. 13 (1996), 159–163.
7. Borchelt, D.R., et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17 (1996), 1005–1013.
8. Callahan, M.J., et al. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158 (2001), 1173–1177.
9. Clinton, L.K., et al. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol. Dis. 28 (2007), 76–82.
10. Cromwell, H.C., Atchley, R.M., Influence of emotional states on inhibitory gating: animals models to clinical neurophysiology. Behav. Brain Res. 276 (2015), 67–75.
11. Cromwell, H.C., et al. Sensory gating: a translational effort from basic to clinical science. Clin. EEG Neurosci. 39 (2008), 69–72.
12. Dekker, A.D., et al. Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. Cortex 73 (2015), 36–61.
13. Dellu, F., et al. Genetic differences in response to novelty and spatial memory using a two-trial recognition task in mice. Neurobiol. Learn. Mem. 73 (2000), 31–48.
14. Eriksen, J.L., Janus, C.G., Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Genet. 37 (2007), 79–100.
15. Fanselow, M.S., Dong, H.W., Are the dorsal and ventral hippocampus functionally distinct structures?. Neuron 65 (2010), 7–19.
16. Fowler, S.W., et al. Genetic modulation of soluble Abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J. Neurosci. 34 (2014), 7871–7885.
17. Fraklin, K.B.J., Paxinos, G., The Mouse Brain in Stereotaxic Coordinates. 2007, Elsevier, NewYork, NY.
18. Golde, T.E., et al. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69 (2011), 203–213.
19. Han, H.J., et al. Strain background influences neurotoxicity and behavioral abnormalities in mice expressing the tetracycline transactivator. J. Neurosci. 32 (2012), 10574–10586.
20. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
21. Hebert, L.E., et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80 (2013), 1778–1783.
22. Herrup, K., Reimagining Alzheimer's disease–an age-based hypothesis. J. Neurosci. 30 (2010), 16755–16762.
23. Hirata-Fukae, C., et al. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 1216 (2008), 92–103.
24. Hua, X., et al. Sex and age differences in atrophic rates: an ADNI study with n = 1368 MRI scans. Neurobiol. Aging 31 (2010), 1463–1480.
25. Hunsaker, M.R., et al. The role of the dentate gyrus, CA3a,b, and CA3c for detecting spatial and environmental novelty. Hippocampus 18 (2008), 1064–1073.
26. Hutter-Paier, B., et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44 (2004), 227–238.
27. Hutton, M., McGowan, E., Clearing tau pathology with abeta immunotherapy-reversible and irreversible stages revealed. Neuron 43 (2004), 293–294.
28. Hyman, B.T., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 8 (2012), 1–13.
29. Jankowsky, J.L., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13 (2004), 159–170.
30. Jankowsky, J.L., et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 25 (2005), 5217–5224.
31. Jankowsky, J.L., et al. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med., 2, 2005, e355.
32. Kesner, R.P., Behavioral functions of the CA3 subregion of the hippocampus. Learn. Mem. 14 (2007), 771–781.
33. Kheirbek, M.A., et al. Differential control of learning and anxiety along the dorsoventral axis of the dentate gyrus. Neuron 77 (2013), 955–968.
34. Kim, S., et al. Evidence that the rab5 effector APPL1 mediates APP-betaCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Mol. Psychiatry, 2015.
35. King, D.L., Arendash, G.W., Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol. Behav. 75 (2002), 627–642.
36. King, D.L., et al. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav. Brain Res. 103 (1999), 145–162.
37. Kojima, N., et al. Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 4761–4765.
38. Kraszpulski, M., et al. The load and distribution of beta-amyloid in brain tissue of patients with Alzheimer's disease. Acta Neurol. Scand. 103 (2001), 88–92.
39. Kulnane, L.S., Lamb, B.T., Neuropathological characterization of mutant amyloid precursor protein yeast artificial chromosome transgenic mice. Neurobiol. Dis. 8 (2001), 982–992.
40. LaClair, K.D., et al. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice. Mol. Neurodegener., 8, 2013, 18.
41. Lee, J.Y., et al. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 7705–7710.
42. Lever, C., et al. Environmental novelty elicits a later theta phase of firing in CA1 but not subiculum. Hippocampus 20 (2010), 229–234.
43. Lewis, J., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25 (2000), 402–405.
44. Li, R., Singh, M., Sex differences in cognitive impairment and Alzheimer's disease. Front. Neuroendocrinol. 35 (2014), 385–403.
45. Lin, K.A., Doraiswamy, P.M., When Mars Versus Venus is Not a Cliche: Gender Differences in the Neurobiology of Alzheimer's Disease. Front. Neurol., 5, 2014, 288.
46. Lin, K.A., et al. Marked gender differences in progression of mild cognitive impairment over 8 years. Alzheimers Dement. (N. Y.) 1 (2015), 103–110.
47. Lyketsos, C.G., et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 7 (2011), 532–539.
48. McDonald, J.H., Handbook of Biological Statistics. 2014, Sparky House Publishing, Baltimore, Maryland.
49. McHugh, T.J., Tonegawa, S., CA3 NMDA receptors are required for the rapid formation of a salient contextual representation. Hippocampus 19 (2009), 1153–1158.
50. Melnikova, T., et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 141 (2006), 1149–1162.
51. Melnikova, T., et al. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J. Neurosci. 33 (2013), 3765–3779.
52. Mielke, M.M., et al. Clinical epidemiology of Alzheimer's disease: assessing sex and gender differences. Clin. Epidemiol. 6 (2014), 37–48.
53. Mitani, Y., et al. Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J. Neurosci. 32 (2012), 2037–2050.
54. Morikawa, T., et al. Power evaluation of various modified Bonferroni procedures by a Monte Carlo study. J. Biopharm. Stat. 6 (1996), 343–359.
55. Nakashiba, T., et al. Transgenic inhibition of synaptic transmission reveals role of CA3 output in hippocampal learning. Science 319 (2008), 1260–1264.
56. Nelson, P.T., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71 (2012), 362–381.
57. Perez, S.E., et al. Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol. Dis. 41 (2011), 338–352.
58. Pimplikar, S.W., et al. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J. Neurosci. 30 (2010), 14946–14954.
59. Pistell, P.J., et al. Acquisition of conditioned taste aversion is impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Neuroscience 152 (2008), 594–600.
60. Poulos, A.M., et al. Compensation in the neural circuitry of fear conditioning awakens learning circuits in the bed nuclei of the stria terminalis. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 14881–14886.
61. Powell, S.B., et al. Prepulse inhibition and genetic mouse models of schizophrenia. Behav. Brain Res. 204 (2009), 282–294.
62. Pusswald, G., et al. Gender-Specific Differences in Cognitive Profiles of Patients with Alzheimer's Disease: Results of the Prospective Dementia Registry Austria (PRODEM-Austria). J. Alzheimers Dis., 2015.
63. Rodgers, S.P., et al. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol. Neurodegener., 7, 2012, 28.
64. Sahara, N., et al. Biochemical Distribution of Tau Protein in Synaptosomal Fraction of Transgenic Mice Expressing Human P301L Tau. Front. Neurol., 5, 2014, 26.
65. Sahay, A., Hen, R., Adult hippocampal neurogenesis in depression. Nat. Neurosci. 10 (2007), 1110–1115.
66. Savonenko, A.V., Borchelt, D.L., Transgenic mouse models of Alzheimer's disease and episodic memory. Dere, E., et al. (eds.) Handbook of Episodic Memory, 2008, Elsevier, 553–573.
67. Savonenko, A.V., et al. Episodic-Like Memory Deficits in the APPswe/PS1dE9 Mouse Model of Alzheimer's Disease: Relationships to b-Amyloid Deposition and Neurotransmitter Abnormalities. Neurobiol. Dis. 18 (2005), 602–617.
68. Savonenko, A.V., et al. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 5585–5590.
69. Schindelin, J., et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9 (2012), 676–682.
70. Shipton, O.A., et al. Left-right dissociation of hippocampal memory processes in mice. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 15238–15243.
71. Skup, M., et al. Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI. NeuroImage 56 (2011), 890–906.
72. Sperling, R.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7 (2011), 280–292.
73. Tamayev, R., D'Adamio, L., Inhibition of gamma-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia. Mol. Neurodegener., 7, 2012, 19.
74. Tamayev, R., et al. beta- but not gamma-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol. Med. 4 (2012), 171–179.
75. Thomas, C., et al. P50 gating deficit in Alzheimer dementia correlates to frontal neuropsychological function. Neurobiol. Aging 31 (2010), 416–424.
76. Vassar, R., et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J. Neurochem. 130 (2014), 4–28.
77. Verret, L., et al. Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J. Neurosci. 27 (2007), 6771–6780.
78. Vuksic, M., et al. 3D-reconstruction and functional properties of GFP-positive and GFP-negative granule cells in the fascia dentata of the Thy1-GFP mouse. Hippocampus 18 (2008), 364–375.
79. Wang, J., et al. Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol. Dis. 14 (2003), 318–327.
80. Webster, S.J., et al. Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front. Genet., 5, 2014, 88.
81. Xu, W., et al. Early hyperactivity in lateral entorhinal cortex is associated with elevated levels of AbetaPP metabolites in the Tg2576 mouse model of Alzheimer's disease. Exp. Neurol. 264 (2015), 82–91.
82. Yetman, M.J., Jankowsky, J.L., Wild-type neural progenitors divide and differentiate normally in an amyloid-rich environment. J. Neurosci. 33 (2013), 17335–17341.